.svg)
A patient-centric oral medicine is only effective if patients are willing to take it consistently. In practice, one of the biggest barriers to adherence is not efficacy, dosage, or convenience, it is taste. Pharmaceutical taste masking has therefore evolved from a formulation refinement into a fundamental requirement in modern oral drug delivery, particularly for patient populations that are highly sensitive to bitterness. to bitterness.
Evidence increasingly supports this shift. A review of paediatric medicines found that poor taste was identified as a barrier to adherence in 27% of studies, contributing to incomplete dose administration in acute therapies and treatment discontinuation in chronic treatment settings. As pharmaceutical manufacturers continue to develop oral dosage forms for increasingly diverse patient populations, improving palatability has become as important as optimising bioavailability and stability.
Historically, taste masking was often viewed as a finishing step in formulation development. Today, it is considered an integral component of patient-centric drug delivery because taste directly influences whether patients accept and continue treatment.
When a bitter API comes into contact with taste receptors in the oral cavity, patients, particularly children and older adults, are more likely to reject or delay medication. This challenge becomes even greater in dosage forms that dissolve or disintegrate in the mouth, where the drug is intentionally exposed to the oral cavity before swallowing.
Consequently, pharmaceutical developers are increasingly designing formulations that balance therapeutic efficacy with patient acceptability from the earliest stages of development. This reflects a broader industry shift towards dosage forms that improve the overall treatment experience rather than focusing solely on pharmacological performance.
The commercial importance of this trend is equally significant. According to Data Insights Market, the global market for pharmaceutical excipients used in taste masking was valued at approximately USD 9.31 billion in 2025 and is projected to reach USD 15.30 billion by 2034, demonstrating sustained investment in technologies that improve medication acceptability. For a pharmaceutical manufacturer, taste masking is no longer simply about improving flavour, but is a strategic differentiator in patient-centric formulation development.
For a deeper discussion on why palatability has become a formulation priority, see our blog on The Need for Pharmaceutical Taste-Masking and Why it Matters.
The importance of pharmaceutical taste masking varies considerably across patient groups, with certain populations depending on palatable formulations for successful therapy.
Children are naturally more sensitive to bitter tastes and are often unable or unwilling to swallow conventional tablets or capsules. Even clinically effective medicines may be rejected purely because of unpleasant taste, creating challenges for caregivers, and increasing the likelihood of incomplete treatment.
As a result, paediatric formulation development increasingly incorporates taste-masked oral granules, orally disintegrating tablets (ODTs), and oral thin films (OTFs). One widely cited example is the taste-masked sodium phenylbutyrate formulation, developed for children with urea cycle disorders, where improved palatability significantly enhanced medicine acceptability.
Our article on Taste Masking of Bitter Drugs for Pediatric Dosage Forms explores these formulation strategies in greater detail.
Older adults frequently experience dysphagia, altered taste perception, and multiple long-term therapies. Together, these factors make medication adherence increasingly dependent on dosage forms that are easy to administer and pleasant to consume.
For geriatric formulations, effective taste-masking pharmaceutical strategies must work alongside technologies that support rapid disintegration, simplified administration, and consistent drug release without compromising therapeutic performance.
Taste masking also plays an important role in patients receiving long-term oral therapies such as antiepileptics (for epilepsy), immunosuppressants (for organ transplant patients), or antiretroviral medicines (for HIV), where consistent, daily dosing over months or years makes palatability critical to adherence. Continuous exposure to unpleasant-tasting medicines can contribute to "taste fatigue", increasing the likelihood of skipped doses over extended treatment periods.
Similarly, patients with dysphagia often rely on oral thin films, liquids, or orally disintegrating dosage forms, making robust taste masking essential because the formulation dissolves directly within the oral cavity.
Our blog on The Indispensable Role of Pharmaceutical Taste-Masking on Specific Patient Demographics discusses these patient-specific formulation considerations further.
There is no universal solution for pharmaceutical taste masking because each API presents different challenges related to solubility, dose, bitterness threshold, particle size, release profile, and intended dosage form. Consequently, formulation scientists often combine multiple technologies to achieve the desired balance between palatability and performance.
One of the most established approaches involves creating physical barriers between the API and taste receptors. Polymer coatings using materials such as HPMC or Eudragit, along with microencapsulation and granulation techniques, delay drug release within the oral cavity while allowing rapid dissolution after swallowing. Similar principles are applied in oral thin films and ODTs, where taste-masked microparticles or nanocrystals minimise immediate exposure of bitter APIs.
Chemical approaches provide another level of control. Ion-exchange resin complexes reduce direct interaction between drug molecules and taste receptors, while cyclodextrin inclusion complexes temporarily encapsulate bitter compounds until they reach the gastrointestinal environment. In some cases, salt selection or prodrug development also contributes to reduced bitterness without affecting therapeutic activity.
Organoleptic strategies continue to complement these structural techniques. Carefully selected flavour systems, sweeteners, cooling agents, and emerging taste-modifying proteins can improve the overall sensory profile, particularly when combined with physical or chemical masking technologies.
The challenge, however, is maintaining the balance between taste masking and product performance. An effective formulation must suppress bitterness in saliva while preserving dissolution, bioavailability, and onset of action once the dosage form reaches its intended absorption site. Achieving this balance remains one of the most important aspects of modern pharmaceutical formulation development.
For a more detailed technical discussion, explore our blog on Taste Masking for Bitter Drugs: A Practical Approach.
The role of pharmaceutical taste masking has expanded significantly as oral drug delivery systems become increasingly patient-centric.
One major driver is the rapid adoption of patient-friendly dosage forms such as oral thin films, orally disintegrating tablets, multiparticulates, and paediatric granules. These formulations offer improved convenience and ease of administration but also increase exposure of APIs to taste receptors, making effective taste masking indispensable.
Pharmaceutical manufacturers increasingly recognise that poor adherence has significant clinical and commercial implications. Medicines that are not taken consistently can reduce therapeutic effectiveness, increase healthcare costs, and negatively affect real-world outcomes. Consequently, taste masking is now incorporated much earlier in formulation development rather than being introduced as a late-stage optimisation.
Across Asia-Pacific, including India, continued investment in polymer science, advanced excipients, oral thin films, and patient-centric delivery technologies is further accelerating innovation in this space.
As oral drug delivery continues to evolve, pharmaceutical taste masking has become far more than a formulation enhancement. It is now a critical component of patient-centric drug delivery, influencing medication acceptance, adherence, and ultimately treatment success across paediatric, geriatric, dysphagic, and chronic-care populations.
Future advances in polymer engineering, taste-modifying technologies, nanotechnology, and innovative oral dosage forms will further strengthen the role of taste masking within pharmaceutical development. For pharmaceutical manufacturers, integrating palatability into formulation design from the outset will be essential to developing oral medicines that combine therapeutic performance with real-world patient acceptance.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
